SCHEMBL3345955

SCHEMBL3345955

FC(F)(F)c1cc(Cl)c2nc(-c3noc(-c4ccccc4Cl)n3)cn2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.60
SMN1; SMN2 Q16637 8/20 0.60
RAB9A P51151 7/20 0.60
NFKB1 P19838 4/20 0.60
NFKB2 Q00653 4/20 0.60
RELA Q04206 4/20 0.60
MAPT P10636 3/20 0.60
CYP1A2 P05177 3/20 0.53
CYP2C19 P33261 3/20 0.53
CYP3A4 P08684 2/20 0.53
CYP2C9 P11712 2/20 0.53
LMNA P02545 1/20 0.53
RECQL P46063 1/20 0.53
PKM P14618 1/20 0.52
ALDH1A1 P00352 2/20 0.49
KDM4E B2RXH2 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
GRM5 P41594 3/20 0.48
CYP2D6 P10635 1/20 0.43
MEN1 O00255 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3340430 0.91 NPC1 (0.58) NPC1SMN1; SMN2RAB9ANFKB1NFKB2
SCHEMBL3338543 0.91 NPC1 (0.60) NPC1SMN1; SMN2RAB9ANFKB1NFKB2
SCHEMBL3340726 0.87 NPC1 (0.60) NPC1SMN1; SMN2RAB9ANFKB1NFKB2
SCHEMBL3342619 0.85 NPC1 (0.58) NPC1SMN1; SMN2RAB9ANFKB1NFKB2
SCHEMBL3343470 0.85 NPC1 (0.58) NPC1SMN1; SMN2RAB9ANFKB1NFKB2
SCHEMBL3343693 0.84 NPC1 (0.57) NPC1SMN1; SMN2RAB9ANFKB1NFKB2
SCHEMBL3337889 0.84 NPC1 (0.57) NPC1SMN1; SMN2RAB9ANFKB1NFKB2
SCHEMBL3340587 0.83 NPC1 (0.61) NPC1SMN1; SMN2RAB9ANFKB1NFKB2
SCHEMBL13303877 0.83 NPC1 (0.49) NPC1SMN1; SMN2RAB9ANFKB1NFKB2
SCHEMBL3339960 0.82 NPC1 (0.48) NPC1SMN1; SMN2RAB9ANFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
WO-2010065760-A1 IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION EXELIXIS, INC. (US) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using S1PR1, S1PR5, S1PR3 NPC1 241/4885SMN1; SMN2 2046/4885RAB9A 2844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.